Castle Biosciences Inc’s recent filing unveils that its Pres. & Chief Exec. Officer MAETZOLD DEREK J unloaded Company’s shares for reported $94851.0 on Apr 21 ’25. In the deal valued at $21.52 per share,4,408 shares were sold. As a result of this transaction, MAETZOLD DEREK J now holds 4,275 shares worth roughly $74513.25.
Then, MAETZOLD DEREK J sold 1,236 shares, generating $26,596 in total proceeds. Upon selling the shares at $21.52, the Pres. & Chief Exec. Officer now owns 74,627 shares.
Before that, MAETZOLD DEREK J sold 3,647 shares. Castle Biosciences Inc shares valued at $73,739 were divested by the Pres. & Chief Exec. Officer at a price of $20.22 per share. As a result of the transaction, MAETZOLD DEREK J now holds 4,440 shares, worth roughly $77389.2.
Guggenheim initiated its Castle Biosciences Inc [CSTL] rating to a Buy in a research note published on December 14, 2023; the price target was $25. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in early January with a ‘”a Sector outperform”‘ rating. Stephens began covering CSTL with “an Overweight” recommendation on January 07, 2022. Lake Street started covering the stock on April 30, 2021. It rated CSTL as “a Buy”.
Price Performance Review of CSTL
On Friday, Castle Biosciences Inc [NASDAQ:CSTL] saw its stock fall -0.95% to $17.43. Over the last five days, the stock has gained 7.14%. Castle Biosciences Inc shares have fallen nearly -34.59% since the year began. Nevertheless, the stocks have fallen -25.09% over the past one year. While a 52-week high of $35.84 was reached on 01/08/25, a 52-week low of $15.45 was recorded on 05/28/25. SMA at 50 days reached $18.40, while 200 days put it at $25.71.
Levels Of Support And Resistance For CSTL Stock
The 24-hour chart illustrates a support level at 17.33, which if violated will result in even more drops to 17.05. On the upside, there is a resistance level at 17.77. A further resistance level may holdings at 17.94. The Relative Strength Index (RSI) on the 14-day chart is 51.97, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.93, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 15.35%. Stochastics %K at 90.61% indicates the stock is a selling.
How much short interest is there in Castle Biosciences Inc?
A steep rise in short interest was recorded in Castle Biosciences Inc stocks on 2025-05-15, dropping by -0.22 million shares to a total of 1.25 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-15 was 1.46 million shares. There was a decline of -17.46%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 10, 2020 when KeyBanc Capital Markets began covering the stock and recommended ‘”an Overweight”‘ rating along with a $70 price target.
